Anupam Rasayan India (ANURAS) Aktienübersicht
Anupam Rasayan India Ltd. beschäftigt sich mit der Auftragssynthese und Herstellung von Spezialchemikalien in Indien, Europa, Japan, Singapur, China, Nordamerika und auf internationaler Ebene. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 0/6 |
| Künftiges Wachstum | 4/6 |
| Vergangene Leistung | 5/6 |
| Finanzielle Gesundheit | 3/6 |
| Dividenden | 1/6 |
Belohnungen
Risikoanalyse
Bei unseren Risikoprüfungen wurden keine Risiken für ANURAS festgestellt.
ANURAS Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Anupam Rasayan India Ltd Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | ₹1,214.60 |
| 52-Wochen-Hoch | ₹1,415.00 |
| 52-Wochen-Tief | ₹1,045.20 |
| Beta | 0.10 |
| 1 Monat Veränderung | -4.20% |
| 3 Monate Veränderung | -11.48% |
| 1 Jahr Veränderung | 8.40% |
| 3 Jahre Veränderung | 27.77% |
| 5 Jahre Veränderung | 61.06% |
| Veränderung seit IPO | 130.56% |
Aktuelle Nachrichten und Updates
Narrative-Update • Jul 21
ANURAS: New Debt Plan Will Pressure Sentiment Despite Long-Term Supply Potential
Analysts have raised their price target for Anupam Rasayan India from ₹1,065 to ₹1,143, citing updated valuation work that reflects a slightly lower discount rate and a revised future P/E assumption, while keeping revenue growth and profit margin expectations broadly unchanged. What's in the News Anupam Rasayan India signed a non-binding Letter of Intent with BASQUEVOLT, a European solid-state lithium battery developer based in Spain, to explore supplying a specialty chemical product for up to 10 years, with potential cumulative revenue of US$300 million, subject to product development and a definitive supply agreement.Narrative-Update • Jul 07
ANURAS: New Credit Issuance Will Pressure Sentiment Despite Recent Platform Milestone
Analysts have lifted their price target for Anupam Rasayan India from ₹976.43 to ₹1,065.00, citing updated assumptions on revenue growth, profit margins, discount rate, and future P/E levels. What's in the News Anupam Rasayan India announced it has become the first company globally to commercialise ETFA (Ethyl trifluoroacetate) using a proprietary continuous flow chemistry platform.
Narrative-Update • Jun 23
ANURAS: Planned Debt Expansion Will Sustain An Unfavorable Risk Profile
Analysts have lifted their fair value estimate for Anupam Rasayan India from ₹640.00 to ₹800.00, reflecting updated assumptions on revenue growth, profit margins and future P/E multiples. What’s in the News for Anupam Rasayan India Anupam Rasayan India announced the commercialisation of ETFA (Ethyl trifluoroacetate) using its proprietary continuous flow chemistry platform, positioning the company as the first globally to produce ETFA at commercial scale using flow technology.
Narrative-Update • Jun 08
ANURAS: Upcoming Debt Raise And Subsidiary Guarantees Will Support Future Upside
Analysts have inched up their fair value estimate for Anupam Rasayan India from ₹1,667.80 to ₹1,680.00, citing updated assumptions around discount rate, revenue growth, profit margins and future P/E multiples. What's in the News The board has scheduled a meeting on May 23, 2026, to consider and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, and to recommend a final dividend for FY 2025-26.Recent updates
Narrative-Update • Jul 21
ANURAS: New Debt Plan Will Pressure Sentiment Despite Long-Term Supply Potential
Analysts have raised their price target for Anupam Rasayan India from ₹1,065 to ₹1,143, citing updated valuation work that reflects a slightly lower discount rate and a revised future P/E assumption, while keeping revenue growth and profit margin expectations broadly unchanged. What's in the News Anupam Rasayan India signed a non-binding Letter of Intent with BASQUEVOLT, a European solid-state lithium battery developer based in Spain, to explore supplying a specialty chemical product for up to 10 years, with potential cumulative revenue of US$300 million, subject to product development and a definitive supply agreement.Narrative-Update • Jul 07
ANURAS: New Credit Issuance Will Pressure Sentiment Despite Recent Platform Milestone
Analysts have lifted their price target for Anupam Rasayan India from ₹976.43 to ₹1,065.00, citing updated assumptions on revenue growth, profit margins, discount rate, and future P/E levels. What's in the News Anupam Rasayan India announced it has become the first company globally to commercialise ETFA (Ethyl trifluoroacetate) using a proprietary continuous flow chemistry platform.Narrative-Update • Jun 23
ANURAS: Planned Debt Expansion Will Sustain An Unfavorable Risk Profile
Analysts have lifted their fair value estimate for Anupam Rasayan India from ₹640.00 to ₹800.00, reflecting updated assumptions on revenue growth, profit margins and future P/E multiples. What’s in the News for Anupam Rasayan India Anupam Rasayan India announced the commercialisation of ETFA (Ethyl trifluoroacetate) using its proprietary continuous flow chemistry platform, positioning the company as the first globally to produce ETFA at commercial scale using flow technology.Narrative-Update • Jun 08
ANURAS: Upcoming Debt Raise And Subsidiary Guarantees Will Support Future Upside
Analysts have inched up their fair value estimate for Anupam Rasayan India from ₹1,667.80 to ₹1,680.00, citing updated assumptions around discount rate, revenue growth, profit margins and future P/E multiples. What's in the News The board has scheduled a meeting on May 23, 2026, to consider and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, and to recommend a final dividend for FY 2025-26.Narrative-Update • May 25
ANURAS: Planned Debt Issuance Will Sustain An Unfavorable Risk Profile
Analysts have lifted their price target on Anupam Rasayan India from ₹625 to ₹640, citing updated assumptions around discount rate, revenue growth, profit margin and future P/E as the key drivers of this change. What's in the News A board meeting is scheduled for May 23, 2026 at 12:45 IST to review and approve the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, and to consider a final dividend on equity shares for FY 2025-26 (company filing).Narrative-Update • May 06
ANURAS: Upcoming Overseas Subsidiary Guarantees Will Support Future Upside
Analysts have slightly adjusted their price target for Anupam Rasayan India to around ₹1,668, reflecting updated assumptions on the discount rate, revenue growth, profit margin and future P/E multiples. What's in the News A special shareholders meeting is scheduled for May 7, 2026 via postal ballot to seek approval for guarantees and security interests linked to the credit facility of wholly owned subsidiary Doriath S.à.r.l. This may include security over the shares and assets of Doriath S.à.r.l and Jayhawk Fine Chemicals Corporation (company filing).Narrative-Update • Apr 21
ANURAS: Upcoming Board Actions On Overseas Units Will Support Future Upside
Analysts have kept their fair value estimate for Anupam Rasayan India broadly unchanged at about ₹1,668, citing slight tweaks to the discount rate, revenue growth, profit margin and future P/E inputs that together support this stable price target view. What's in the News A board meeting is scheduled on Feb 12, 2026, to consider 12,000 shares of Doriath S.à r.l.; 1,800 shares of Batam S.à r.l. representing a 15% equity stake; potential credit facility transactions; an ECB facility agreement with Axis Bank Limited, IBU GIFT City; appointment of Axis Trustee Services Limited as security trustee; and other matters (Key Developments).Narrative-Update • Apr 07
ANURAS: Overseas Subsidiary Financing Structure Will Support Future Upside Potential
Analysts have nudged their fair value estimate for Anupam Rasayan India to about ₹1,668. This change is linked to updated assumptions on discount rate, revenue growth, profit margin and future P/E.Narrative-Update • Mar 23
ANURAS: Upcoming Credit Facilities And Subsidiary Transactions Will Pressure Sentiment Through 2026
The analyst price target for Anupam Rasayan India has been revised from ₹922 to ₹976, with analysts citing updated assumptions on the discount rate, revenue growth, profit margins and future P/E multiples to support the new view. What's in the News Board meeting on Feb 12, 2026 to review 12,000 shares of Doriath S.à r.l., a wholly owned subsidiary, and 1,800 shares of Batam S.à r.l. representing a 15% equity stake in Batam (Key Developments).Narrative-Update • Mar 09
ANURAS: Overseas Acquisitions And Expanded Borrowing Capacity Will Drive Future Upside
Analysts have nudged their fair value estimate for Anupam Rasayan India to about ₹1,668 per share, reflecting slightly adjusted assumptions around discount rate, revenue growth, profit margin and future P/E that leave the overall valuation picture broadly unchanged. What's in the News A board meeting is scheduled for Feb 12, 2026 to review the potential acquisition of 12,000 shares of Doriath S.à r.l. and 1,800 shares of Batam S.à r.l. representing 15% equity in Batam, and to consider new credit facilities and related security arrangements with Axis Bank Limited and Axis Trustee Services Limited (Key Developments).Narrative-Update • Feb 23
ANURAS: Future Overseas Acquisitions And Borrowing Headroom Will Redefine Upside Potential
Analysts have lifted their fair value estimate for Anupam Rasayan India from ₹1,305.00 to about ₹1,667.80, reflecting updated assumptions around discount rate, revenue growth, profit margin and future P/E expectations. What's in the News Board meeting on Feb 12, 2026 to review acquisition of 12,000 shares of Doriath S.à r.l., a wholly owned subsidiary, and 1,800 shares in Batam S.à r.l. representing a 15% equity stake, along with related credit facility arrangements, including an ESCB Facility with Axis Bank Limited, IBU GIFT City, and appointment of Axis Trustee Services Limited as security trustee under an ECB Facility (company board notice).Narrative-Update • Feb 08
ANURAS: Planned Acquisition And Higher Leverage Will Sustain An Unfavorable Risk Profile
Analysts have kept their fair value estimate for Anupam Rasayan India steady at ₹625.00 per share, highlighting slightly adjusted assumptions around discount rate, revenue growth and profit margin as the key drivers behind the unchanged target. What's in the News A board meeting is scheduled for Feb 14, 2026 to consider and approve unaudited financial results for the quarter and nine months ended Dec 31, 2025, providing the next formal update on recent financial performance (company filing).Narrative-Update • Jan 25
ANURAS: Planned Acquisition And Higher Leverage Will Drive An Unfavorable Risk Profile
Analysts have raised their price target on Anupam Rasayan India from ₹520 to ₹625, citing updated assumptions for profit margins, growth and P/E that they consider better reflect the stock’s risk profile and return outlook. What's in the News Board meeting on Dec 09, 2025 to consider and approve the acquisition of Monitchem Kansas S.à r.l and its subsidiaries, along with a related loan receivable from CABB GmbH, and the execution of a Sale and Purchase Agreement (company filing).Analyseartikel • Jan 21
Investors Met With Slowing Returns on Capital At Anupam Rasayan India (NSE:ANURAS)
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Firstly, we'll...Narrative-Update • Jan 08
ANURAS: Planned Acquisition And Higher Leverage Will Pressure Sentiment Through 2026
Analysts have lifted their fair value estimate for Anupam Rasayan India from ₹905 to about ₹922, citing updated assumptions for the discount rate, long term revenue growth, profit margins and the future P/E multiple. What's in the News The board will meet on Dec 09, 2025 to consider and approve the acquisition of Monitchem Kansas S.à r.l and its subsidiaries, along with a related loan receivable from CABB GmbH, and to authorize a Sale and Purchase Agreement and postal ballot notice.Analyseartikel • Dec 16
Is Anupam Rasayan India (NSE:ANURAS) A Risky Investment?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Narrative-Update • Dec 14
ANURAS: Acquisition And Auditor Shift Will Pressure Sentiment Through 2026
Analysts have nudged their price target for Anupam Rasayan India slightly higher to ₹905.0 from ₹905, citing marginal improvements in the discount rate and long term profitability assumptions while keeping growth expectations largely intact. What's in the News Board meeting scheduled for December 09, 2025 to consider the acquisition of Monitchem Kansas S.à r.l and its subsidiaries, along with related loan receivable and Sale and Purchase Agreement approvals (company filing) Special shareholders meeting via postal ballot on January 09, 2026 to seek investor approval for the proposed acquisition and related resolutions (company filing) Special shareholders meeting via postal ballot on December 22, 2025, with voting conducted through remote e-voting (company filing) Board meeting held on November 21, 2025 to approve the postal ballot notice, set the cut-off date, define the e-voting window, and appoint a scrutinizer for the postal ballot process (company filing) Board meeting on October 17, 2025 to review and approve unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (company filing) Shareholders at the September 26, 2025 AGM approved the appointment of Natvarlal Vepari and Co., Chartered Accountants, Surat, as the company’s new statutory auditor (company filing) Valuation Changes Fair Value: Maintained effectively flat at ₹905.0, reflecting no material change in the intrinsic value estimate.Narrative-Update • Nov 30
ANURAS: Auditor Transition And Board Actions Will Pressure Sentiment Through 2025
Analysts have maintained their fair value estimate for Anupam Rasayan India at ₹905.00, citing stable forecast assumptions, even with minor adjustments in financial metrics. What's in the News The company scheduled a Special/Extraordinary Shareholders Meeting on December 22, 2025, to be conducted via postal ballot in India.Analyseartikel • Nov 20
Anupam Rasayan India Ltd (NSE:ANURAS) Investors Are Less Pessimistic Than Expected
When you see that almost half of the companies in the Chemicals industry in India have price-to-sales ratios (or "P/S...Narrative-Update • Nov 16
ANURAS: Net Profit Margin Will Weaken Amid Management And Auditor Changes
Analysts have slightly reduced their price target for Anupam Rasayan India to ₹905.00 per share, citing modest adjustments in profit margin expectations and valuation assumptions. What's in the News A board meeting is scheduled for October 17, 2025 to consider and approve the unaudited financial results for the quarter and half year ended September 30, 2025 (Company Filing).Narrative-Update • Nov 01
ANURAS: Slowing Revenue Expansion Will Pressure Margins Despite Profit Recovery
Analysts have raised their price target for Anupam Rasayan India from ₹884.29 to ₹909.29, citing improved profit margin expectations even though projected revenue growth is expected to moderate. What's in the News The board meeting is scheduled for October 17, 2025, to consider and approve unaudited financial results for the quarter and half year ended September 30, 2025 (Key Developments).Narrative-Update • Oct 18
Growing Contract Wins And Tightening Margins Will Shape Future Prospects
Analysts have revised their price target for Anupam Rasayan India upward from ₹838 to ₹884. They cited slight adjustments in the discount rate and an upward recalibration of fair value in their latest models.Analyseartikel • Oct 02
Returns On Capital At Anupam Rasayan India (NSE:ANURAS) Have Hit The Brakes
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...Narrative-Update • Aug 22
Expanding Pharma And Polymer Segments To Drive Future Success
Despite a notable reduction in consensus revenue growth forecasts, expectations for Anupam Rasayan India's earnings multiple have increased, resulting in a higher analyst price target now at ₹837.86. What's in the News Board meeting scheduled to consider and approve unaudited Q1 FY26 financial results.Analyseartikel • May 28
Anupam Rasayan India Ltd Just Missed EPS By 7.1%: Here's What Analysts Think Will Happen Next
Investors in Anupam Rasayan India Ltd ( NSE:ANURAS ) had a good week, as its shares rose 3.0% to close at ₹991...Analyseartikel • Apr 08
Anupam Rasayan India Ltd (NSE:ANURAS) Not Lagging Industry On Growth Or Pricing
When you see that almost half of the companies in the Chemicals industry in India have price-to-sales ratios (or "P/S...
Neues Narrative • Mar 11
Expanding Pharma And Polymer Segments To Drive Future Success
Pharma and Polymer growth, energy cost cuts, and a robust pipeline with new molecules will drive future revenue growth and improve net margins.Analyseartikel • Nov 25
Anupam Rasayan India's (NSE:ANURAS) Problems Go Beyond Weak Profit
A lackluster earnings announcement from Anupam Rasayan India Ltd ( NSE:ANURAS ) last week didn't sink the stock price...Analyseartikel • Nov 18
Earnings Report: Anupam Rasayan India Ltd Missed Revenue Estimates By 9.2%
The second-quarter results for Anupam Rasayan India Ltd ( NSE:ANURAS ) were released last week, making it a good time...Analyseartikel • Nov 02
Anupam Rasayan India (NSE:ANURAS) Hasn't Managed To Accelerate Its Returns
There are a few key trends to look for if we want to identify the next multi-bagger. One common approach is to try and...Analyseartikel • Aug 24
Time To Worry? Analysts Just Downgraded Their Anupam Rasayan India Ltd (NSE:ANURAS) Outlook
Today is shaping up negative for Anupam Rasayan India Ltd ( NSE:ANURAS ) shareholders, with the analysts delivering a...Analyseartikel • Aug 17
Anupam Rasayan India Ltd Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
As you might know, Anupam Rasayan India Ltd ( NSE:ANURAS ) last week released its latest quarterly, and things did not...Analyseartikel • May 26
Anupam Rasayan India's (NSE:ANURAS) Shareholders Have More To Worry About Than Only Soft Earnings
A lackluster earnings announcement from Anupam Rasayan India Limited ( NSE:ANURAS ) last week didn't sink the stock...Analyseartikel • May 22
Analyst Estimates: Here's What Brokers Think Of Anupam Rasayan India Limited (NSE:ANURAS) After Its Full-Year Report
Last week saw the newest annual earnings release from Anupam Rasayan India Limited ( NSE:ANURAS ), an important...Analyseartikel • Dec 30
What You Can Learn From Anupam Rasayan India Ltd's (NSE:ANURAS) P/E
When close to half the companies in India have price-to-earnings ratios (or "P/E's") below 29x, you may consider Anupam...Analyseartikel • Nov 03
Anupam Rasayan India (NSE:ANURAS) Might Have The Makings Of A Multi-Bagger
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Amongst other things...Analyseartikel • Jul 13
Is Now The Time To Put Anupam Rasayan India (NSE:ANURAS) On Your Watchlist?
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Analyseartikel • Jun 24
Anupam Rasayan India's (NSE:ANURAS) Returns On Capital Are Heading Higher
To find a multi-bagger stock, what are the underlying trends we should look for in a business? Amongst other things...Aktionärsrenditen
| ANURAS | IN Chemicals | IN Markt | |
|---|---|---|---|
| 7D | 0.6% | 1.7% | 1.3% |
| 1Y | 8.4% | 1.3% | 5.9% |
Rendite im Vergleich zur Industrie: ANURAS übertraf die Branche Indian Chemicals , die im vergangenen Jahr eine Rendite von 1.3 erzielte.
Rendite vs. Markt: ANURAS übertraf den Markt Indian, der im vergangenen Jahr eine Rendite von 5.9 erzielte.
Preisvolatilität
| ANURAS volatility | |
|---|---|
| ANURAS Average Weekly Movement | 2.5% |
| Chemicals Industry Average Movement | 6.0% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in IN Market | 9.0% |
| 10% least volatile stocks in IN Market | 3.7% |
Stabiler Aktienkurs: ANURAS hatte in den letzten 3 Monaten im Vergleich zum Indian -Markt keine signifikante Preisvolatilität.
Volatilität im Zeitverlauf: ANURASDie wöchentliche Volatilität (3%) ist im vergangenen Jahr stabil geblieben.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 1984 | 2,606 | Gopal Agrawal | www.anupamrasayan.com |
Anupam Rasayan India Ltd ist in der Auftragssynthese und Herstellung von Spezialchemikalien in Indien, Europa, Japan, Singapur, China, Nordamerika und international tätig. Das Unternehmen ist in zwei Segmenten tätig: Spezialchemikalien für die Biowissenschaften und andere Spezialchemikalien. Das Unternehmen bietet Spezialchemikalien für die Biowissenschaften an, z. B. Agro-Zwischenprodukte und Agro-Wirkstoffe für die agrochemische Industrie, antibakterielle und UV-Schutz-Zwischenprodukte und -Inhaltsstoffe für die Körperpflegeindustrie sowie Zwischenprodukte und wichtige Ausgangsstoffe für pharmazeutische Wirkstoffe.
Anupam Rasayan India Ltd's Grundlagenzusammenfassung
| ANURAS grundlegende Statistiken | |
|---|---|
| Marktanteil | ₹138.28b |
| Gewinn(TTM) | ₹1.70b |
| Umsatz(TTM) | ₹23.65b |
81.3x
Kurs-Gewinn-Verhältnis 5.8x
Kurs-Umsatz-VerhältnisIst ANURAS zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| ANURAS Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | ₹23.65b |
| Kosten der Einnahmen | ₹13.23b |
| Bruttogewinn | ₹10.42b |
| Sonstige Ausgaben | ₹8.72b |
| Gewinn | ₹1.70b |
Zuletzt gemeldete Gewinne
Mar 31, 2026
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | 14.94 |
| Bruttomarge | 44.06% |
| Nettogewinnspanne | 7.19% |
| Schulden/Eigenkapital-Verhältnis | 39.2% |
Wie hat sich ANURAS auf lange Sicht entwickelt?
Historische Performance und VergleicheDividenden
0.1%
Aktuelle Dividendenrendite10%
AusschüttungsquoteUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/08/08 01:08 |
| Aktienkurs zum Tagesende | 2026/08/07 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2026/03/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Anupam Rasayan India Ltd wird von 10 Analysten beobachtet. 3 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Ankur Periwal | Axis Capital Limited |
| Satish Kumar | CGS International |
| Dane Leone | CGS International |